Evolus licenses IBSA's Profhilo for U.S. skin quality market

Evolus, Inc. announced on July 8, 2026 that it had signed an exclusive licensing and distribution agreement with Swiss pharmaceutical company IBSA to bring Profhilo to the United States. According to the company's 8-K, on July 7, 2026, Evolus and IBSA entered a License, Supply and Distribution Agreement under which IBSA gave Evolus exclusive rights to develop, commercialize, and distribute Profhilo, described as an injectable hyaluronic acid product for skin-quality use, for the U.S. aesthetics and dermatology market.¹ The deal also gives Evolus the ability to negotiate for other products in the Profhilo brand family and related line extensions in that same U.S. field.¹

Under the agreement, Evolus will pay for and lead the U.S. development, clinical, and regulatory work needed for FDA approval, and will own any resulting approval and related regulatory filings.¹ Once approved, Evolus will buy the product from IBSA under a transfer-price arrangement that can be adjusted periodically per the agreement's terms.¹ The contract includes minimum purchase requirements starting in the fourth year after commercial launch, with failure to meet them potentially converting Evolus's exclusivity to non-exclusive rights or ending the agreement, subject to some exceptions.¹ Notably, Evolus is not required to make any upfront or milestone payments to IBSA.¹

The agreement's initial term runs fifteen years from the first FDA approval of the product, with options to renew for additional five-year periods under its terms.¹

Evolus said in its release that the deal is not expected to affect its previously stated 2026 revenue, operating expense, or operating profit outlook, nor its 2028 revenue or profitability targets.¹ The full contract will be filed as an exhibit with Evolus's Form 10-Q for the quarter ending September 30, 2026.¹